![]() | |
Clinical data | |
---|---|
Trade names | Aristada, Aristada Initio |
Other names | N-Lauroyloxymethylaripiprazole; ALKS-9070; ALKS-9072; RDC-3317; Dodecanoic acid-[7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2-oxo-1(2H)-quinolinyl]methyl ester |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615048 |
Pregnancy category |
|
Routes of administration | Intramuscular |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.261.570 |
Chemical and physical data | |
Formula | C36H51Cl2N3O4 |
Molar mass | 660.72 g·mol−1 |
3D model (JSmol) | |
| |
|
Aripiprazole lauroxil, sold under the brand name Aristada, is a long-acting injectable atypical antipsychotic that was developed by Alkermes.[3][4][5] It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia.[3][4][5] Aripiprazole lauroxil was approved by the U.S. Food and Drug Administration (FDA) on 5 October 2015.[6][7]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search